21:14 Wed 26 Mar 2025
MaxCyte, Inc. - Correction: Vesting of RSUs and PDMR Dealing
MaxCyte, Inc.
("MaxCyte" or the "Company")
Vesting of RSUs and PDMR Dealing
The following amendment has been made to the Publication of Vesting of RSUs and PDMR Dealing released on
The RNS did not include the number of shares of previously granted restricted stock units.
All other details remain unchanged.
The full amended text is shown below.
Following the Vesting and Sale,
The information in the tables below is provided in accordance with the requirements of the
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 25 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.
MaxCyte Contacts:
|
US IR Adviser Gilmartin Group |
+1 415-937-5400
|
|
Nominated Adviser and Joint Corporate Broker Panmure Liberum Corporate Broking |
+44 (0)20 7886 2500 |
|
ICR Healthcre |
+44 (0)203 709 5700
|
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chief Financial Officer |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
MaxCyte Inc. |
|||
|
b)
|
LEI
|
54930053YHXULRFCU991 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Common stock of |
|||
|
|
|
||||
|
Identification code |
US57777K1060 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Acquisition of common stock following vesting of RSUs |
|||
|
c)
|
Price(s) and volume(s) |
|
RSUs:
|
|
|
|
|
|
Exercise Price(s) |
Volume(s) |
|
|
|
|
|
N/A |
20,313 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
20,313 |
||||
|
|
|
||||
|
- Price |
N/A |
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
17 March, 2025 |
|||
|
f)
|
Place of the transaction
|
US Stock Exchange, Nasdaq |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||
|
a)
|
Name
|
|
|
|
2
|
Reason for the notification
|
||
|
a)
|
Position/status
|
Chief Financial Officer |
|
|
b)
|
Initial notification /Amendment
|
Initial notification |
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
MaxCyte Inc. |
|
|
b)
|
LEI
|
54930053YHXULRFCU991 |
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||
|
a)
|
Description of the financial instrument, type of instrument |
Common stock of |
|
|
|
|
||
|
Identification code |
US57777K1060 |
||
|
|
|
||
|
b)
|
Nature of the transaction
|
Sale of common stock to satisfy withholding tax liabilities as a condition of vesting of RSUs
|
|
|
c)
|
Price(s) and volume(s) |
|
|
|
|
Price(s) |
Volume |
|
|
|
|
153 |
|
|
|
|
30 |
|
|
|
|
427 |
|
|
|
|
74 |
|
|
|
|
941 |
|
|
|
|
49 |
|
|
|
|
1676 |
|
|
|
|
37 |
|
|
|
|
904 |
|
|
|
|
103 |
|
|
|
$3.1900 |
902 |
|
|
|
$3.1950 |
62 |
|
|
|
$3.2000 |
497 |
|
|
|
$3.2050 |
166 |
|
|
|
$3.2100 |
664 |
|
|
|
$3.2150 |
254 |
|
|
|
|
||
|
d)
|
Aggregated information |
|
|
|
|
|
||
|
- Aggregated volume |
6,939 |
||
|
|
|
||
|
- Price |
|
||
|
|
|
||
|
e)
|
Date of the transaction
|
18 March, 2025 |
|
|
f)
|
Place of the transaction
|
US Stock Exchange, Nasdaq |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes,...
FOR OUR FULL DISCLAIMER CLICK HERE